t½ and the Cl in neonates are similar to those in adults (SmPC). Children generally metabolize benzodiazepine agonists faster than juveniles and adults.
The following kinetic parameters have been found after intravenous administration in neonates [Andre]:
| Vd (l/kg) | Cl (l/h/kg) | t1/2 (h) | |
| PNA 0.5-40 days; Dose 0.1 mg/kg (n=8) |
1,5-11,0 | PNA 0,5-2,5 days (n=5): 0,03-0,06 PNA 25 days;40 dagen (n=2): 0,14 resp 0,15 |
19,4-140 |
| PNA 0,5-6 days; Dose 0.2 mg/kg (n=9) |
1,8-4,4 | 0,04-0,07 | 22,5-74 |
| PNA 44 days; Dose 0.2 mg/kg (n=1) |
5,0 | 0,153 | 22,5-74 |
The following pharmacokinetic data in children were found after oral administration:
| Age | n= | Dose | Cl (ml/hour/kg) | t1/2 (hour) | Reference |
| 2-18 years | 10 | 0,01-0,085 mg/kg/day in 3-4 doses | 7-64 (mean 25±19) |
- | Walson et al. 1996 |
| 6-13 years | 4 | 0,028-0,083 mg/kg/day in 3 doses | - | 22,1-32,7 (mean 28,7) | Dreifuss et al. 1975 |
No information is present at this moment.
No information is present at this moment.
| Epilepsy |
|---|
|
| Status epilepticus |
|---|
|
| Acute anxiety (short use) |
|---|
|
There are no known data on dose adjustment in renal impairment. According to the manufacturer, renal impairment in adults does not affect the pharmacokinetics of clonazepam and does not require dose adjustment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Drowsiness and hypotonia.
In infants and young children: increased salivation and bronchial hypersecretion.
Especially in children, paradoxical reactions occur with restlessness, agitation, irritability, aggression, nervousness, hostility, anxiety, sleep disturbances, delusions, anger, nightmares, abnormal dreams, hallucinations, psychoses, hyperactivity, inappropriate behavior and other behavioral disturbances. Solated cases of reversible development of preterm secondary sexual characteristics in children (incomplete pubertas praecox) have been reported (SmPC).
In neonates and particularly in preterm infants, benzyl alcohol (component of the solution for injection of Rivotril) has been associated with permanent neuropsychiatric abnormalities and multi-organ failure (SmPC).
Undiluted administration of the drip solution may cause irritation and blue discoloration of the oral mucosa.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Intravenous administration under respiratory and blood pressure monitoring (SmPC).
In infants and toddlers, because of increased salivation and bronchial hypersecretion, adequate monitoring is required to ensure that the airways remain clear (SPC).
In these patients, very careful dose adjustment, generally dose reduction, and great care in use are required (SPC).
Slowly taper off over at least 2 weeks.
Avoid administering directly from the dropper bottle into the mouth to prevent incorrect dosing (e.g., overdose).Preferably mix the drops with water, tea, or juice and administer with a spoon.
In infants and children < 3 years of age, the benzyl alcohol in the injection may cause toxic and anaphylactoid reactions (SPC).
Rivotril drops contain propylene glycol. co-administration with an alcohol dehydrogenase substrate, such as ethanol, may cause adverse reactions in children less than 5 years of age.
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Barbiturates and derivatives | ||
|---|---|---|
| N03AA02 | ||
| N03AA03 | ||
| Hydantoin derivatives | ||
|---|---|---|
| N03AB02 | ||
| Succinimide derivatives | ||
|---|---|---|
| N03AD01 | ||
| Carboxamide derivatives | ||
|---|---|---|
| N03AF01 | ||
| N03AF02 | ||
| N03AF03 | ||
| Fatty acid derivatives | ||
|---|---|---|
| N03AG01 | ||
| N03AG04 | ||
| Other antiepileptics | ||
|---|---|---|
| N03AX23 | ||
| N03AX24 | ||
| N03AX10 | ||
| N03AX26 | ||
| N03AX18 | ||
| N03AX09 | ||
| N03AX14 | ||
| N03AX22 | ||
| N03AX16 | ||
| N03AX17 | ||
| N03AX03 | ||
| N03AX11 | ||
| N03AX15 | ||